Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

22.08USD
4:00pm EDT
Change (% chg)

$-1.57 (-6.64%)
Prev Close
$23.65
Open
$22.80
Day's High
$22.98
Day's Low
$21.90
Volume
1,130,259
Avg. Vol
230,031
52-wk High
$27.78
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Achaogen announces pricing of public offering of common stock
8:00am EDT 

May 25 (Reuters) - Achaogen Inc :Achaogen announces pricing of public offering of common stock.Says public offering of 5.00 million common shares priced at $22.50per share.  Full Article

Achagaon says FDA grants its antibiotic Plazomicin "breakthrough therapy" status
Tuesday, 23 May 2017 04:07pm EDT 

May 23 (Reuters) - Achaogen Inc :Plazomicin granted fda breakthrough therapy designation.Co intends to include care trial data, along with data from epic trial, in an nda submission in second half of 2017.  Full Article

Achaogen offers up to 5 mln shares in public offering
Tuesday, 23 May 2017 04:03pm EDT 

May 23 (Reuters) - Achaogen Inc :Achaogen announces proposed public offering of common stock.Achaogen inc- commenced an underwritten public offering of up to 5 million shares of its common stock.Achaogen - expects to use net proceeds from offering to fund its ongoing development and preparation for potential commercialization of plazomicin.  Full Article

Achaogen files for potential mixed shelf offering
Monday, 8 May 2017 05:31pm EDT 

May 8 (Reuters) - Achaogen Inc ::Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

Achaogen reports Q1 loss per share $0.93
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - Achaogen Inc :Achaogen reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.93.Q1 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Achaogen Inc - plazomicin registration activities on track; nda submission planned for second half of 2017.Achaogen Inc - plan to initiate a phase 1 c-scape clinical trial program in Q2 of 2017.Achaogen Inc - contract revenue totaled $7.5 million for Q1 of 2017 compared to $5.8 million for same period of 2016..  Full Article

Achaogen receives 20 mln in grant funding and equity investment
Friday, 5 May 2017 08:01am EDT 

May 5 (Reuters) - Achaogen Inc : :Achaogen - receives 20 million in grant funding and equity investment from Bill & Melinda Gates Foundation to develop antibodies against gram-negative bacteria.  Full Article

Robert Duggan reports 5.7 pct stake in Achaogen Inc, as of March 21, 2017 - SEC filing
Tuesday, 28 Mar 2017 04:09pm EDT 

Achaogen Inc : Robert Duggan reports 5.7 percent stake in Achaogen Inc, as of March 21, 2017 - SEC filing .Robert Duggan - purchased Achaogen Inc's shares based on the reporting person's belief that the shares when purchased "were undervalued".  Full Article

Achaogen says on March 14, Chief Medical Officer Ian Friedland and co agreed on terms of his resignation
Monday, 20 Mar 2017 04:09pm EDT 

Achaogen Inc : Achaogen - on march 14, ian friedland, chief medical officer, co agreed on terms of his resignation from his position - sec filing . Achaogen - effective as of march 16, amended that certain consulting agreement with planet pharma, a firm in which friedland is associated as amended .Achaogen - pursuant to amended consulting agreement, friedland to be available to perform certain services to co through july 31, on an as-needed basis.  Full Article

Achaogen Q4 loss per share $1.04
Tuesday, 14 Mar 2017 04:01pm EDT 

Achaogen Inc : Achaogen reports fourth quarter and full year 2016 financial results and provides corporate update . Q4 loss per share $1.04 . Q4 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S .Qtrly contract revenue $10.7 million versus $4.7 million.  Full Article

Achaogen says Plazomicin NDA submission planned for second half of 2017
Wednesday, 1 Mar 2017 04:01pm EST 

Achaogen Inc : Achaogen inc- plazomicin nda submission planned for second half of 2017 .Achaogen inc- plan to initiate clinical trial of orally-administered antibacterial candidate for esbl+ infections, c-scape, in 2017.  Full Article

More From Around the Web